The increasing prevalence of the chronic obstructive pulmonary disease is projected to boost the global emphysema market at an approximate CAGR of 4.20%

Pune, India, April 9, 2023 /press release/- Market Research Future Published a Half Cooked Research Report on Global Emphysema Market Research Report.

Emphysema Market Highlights

The global emphysema market is expected to grow UDS 19.7 Billion at a CAGR of 4.20% during the forecast period 2023 to 2030.

Factors such as the increasing prevalence of the chronic obstructive pulmonary disease and the rising therapeutics’ demand are estimated to drive the market growth during the forecast period. Additionally, advancements in diagnostic technologies boost the market. However, low awareness and lack of healthcare services in the middle- and low-income countries are estimated to restrain the market growth during the projected period.

Segmentation

The global emphysema market is segmented on the basis of type, diagnosis, treatment, and end-user.

On the basis of type, the market is segmented into centrilobular and panlobular emphysema.

On the basis of diagnosis, the market is segmented into imaging tests, lung function tests, and others. The imaging test is further segmented into chest X-ray and CT scan. On the basis of treatment, the market is segmented into medications, therapy, and surgery. Medications are further segmented into smoking cessation drugs, bronchodilators, inhaled steroids, antibiotics, and leukotriene modifiers. Therapy is further segmented into pulmonary rehabilitation, nutrition therapy, gene therapy, and supplemental oxygen. Surgery is further segmented into lung volume reduction surgery, lung transplant, and bullectomy. On the basis of end-user, the market is segmented into hospitals and clinics, surgical centers, and others.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Emphysema Market Research Report

Regional Analysis

The Americas dominates the global emphysema market owing to the rising prevalence of the chronic obstructive pulmonary disease and presence of a well-developed healthcare sector within the region. Moreover, the increasing healthcare expenditure and the presence of key players within the regional boundaries provide a favorable background for the market growth. Europe is second in the global emphysema market. Factors such as increasing availability of funds for research and a huge patient population followed by a well-developed healthcare sector drive the market within the region. Asia Pacific is estimated to be the fastest growing market for emphysema. This can be attributed to the presence of developing economies such as India and China and huge patient population. Moreover, rising healthcare expenditure and a rapidly developing healthcare sector boost the market growth within the region. On the other hand, the Middle East and Africa has the least share in the global emphysema market due to the low per capita healthcare expenditure and stringent government policies, especially within the African region. It is estimated that the Middle East holds a majority of the market within the Middle Eastern and African region.

Key Players

Some of the key players in this market are Intrexon Corporation, Pulmonx Inc., Halozyme Therapeutics, Inc., Mariposa Health Limited, PneumRx, Uptake Medical Corporation, Icure Pharmaceuticals, Inc., Pfizer, Inc., BTG International’s, Olympus Corporation, Kamada Limited, Emphasys Medical, Inc. and others.